Posted by Michael Wonder on 18 Nov 2023
Almirall receives European Commission Approval of Ebglyss (lebrikizumab) for moderate to severe atopic dermatitis
17 November 2023 - Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription.
Almirall announced today that the European Commission has approved Ebgylss (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe atopic dermatitis, who are candidates for systemic therapy.
